---
title: "Anika Therapeutics completes sale of Parcus Medical to Medacta Group"
url: "https://aibio.space/news/anika-therapeutics-completes-sale-parcus-medical-medacta-group/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-11"
section: "Mergers"
tickers: "NASDAQ:ANIK"
source: "https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/exh_991.htm"
summary: "The deal closed on March 7, 2025 for an undisclosed amount, paid in cash at closing. Anika will now focus on hyaluronic acid pain products and regenerative"
---

By the aibio.space news desk.

Sources

- [Anika Therapeutics, Inc. 8-K (2025-03-11)](https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/exh_991.htm)

[ANIK](https://aibio.space/companies/anika-therapeutics/)

2025-03-11

# Anika Therapeutics completes sale of Parcus Medical to Medacta Group

Tickers [ANIK](https://aibio.space/companies/anika-therapeutics/)

The deal closed on March 7, 2025 for an undisclosed amount, paid in cash at closing. Anika will now focus on hyaluronic acid pain products and regenerative solutions.

## Key facts

- **Company**: Anika Therapeutics, Inc. (NASDAQ: ANIK)

- **News type**: Mergers

- **Primary source**: [Anika Therapeutics, Inc. 8-K (2025-03-11)](https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/exh_991.htm)

*A city skyline seen across a river. Photo: Matt Bango, CC0, via StockSnap. The picture shows the field, not the companies named.*

Anika Therapeutics, Inc. completed the previously announced sale of its Parcus Medical business to Medacta Group SA on March 7, 2025.

The amount was not disclosed. The company said in a [press release](https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/exh_991.htm) that total cash consideration was received at closing, subject to customary post-closing adjustments.

The divestiture is part of a strategic review Anika announced earlier. With Parcus sold, the company said it will focus on its core hyaluronic acid technology for osteoarthritis pain management and on its Regenerative Solutions portfolio.

"The sale of Parcus marks a critical step forward as we achieve the goals of our previously announced strategic review," said Cheryl R. Blanchard, Ph.D., president and chief executive officer.

Anika and Medacta agreed to work together on the transition of the business for employees, distributor agents, surgeon customers and patients.

Goodwin Procter served as legal counsel and Piper Sandler acted as exclusive financial advisor to Anika on the sale.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ANIK

Anika Therapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Mergers

Mergers

### [InMed sets November 5 record date for CVRs tied to Mentari merger](https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/)

Oct 27, 2026

Mergers

### [Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger](https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/)

Oct 26, 2026

Mergers

### [Skye Bioscience files preliminary proxy for its Redx Pharma acquisition](https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/)

Oct 26, 2026

---
Source page: https://aibio.space/news/anika-therapeutics-completes-sale-parcus-medical-medacta-group/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Anika Therapeutics completes sale of Parcus Medical to Medacta Group", 2025-03-11, https://aibio.space/news/anika-therapeutics-completes-sale-parcus-medical-medacta-group/